Product Description
αLTβR (PF-07329640): Activating the Lymphotoxin-β Receptor, a Highly Differentiated Approach to Immunotherapy. (Sourced from: https://s28.q4cdn.com/781576035/files/doc_downloads/2024/02/29/Pfizer-Oncology-Innovation-Day-Presentation_FINAL.pdf)
Mechanisms of Action: LTBR Inhibitor
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for PF-07329640](https://pryzm-maps.s3.us-west-2.amazonaws.com/666666current_maps.png)
Countries in Clinic: Puerto Rico, United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Colorectal Cancer|Melanoma|Non-Small-Cell Lung Cancer|Transitional Cell Carcinoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
LTbR | P1 |
Active, not recruiting |
Colorectal Cancer|Melanoma|Non-Small-Cell Lung Cancer|Transitional Cell Carcinoma |
2024-08-16 |